← All trials
NCT00300053
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2006
- Primary completion
- Mar 31, 2008
- Completion date
- Mar 31, 2009
- First posted
- Mar 8, 2006
- Last posted
- Jan 26, 2021
- Enrollment
- 321
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Lisata Therapeutics, Inc.Lead sponsor
- Lisata Therapeutics, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.